[Review: clinical outcome after living donor liver transplantation in patients with hepatitis C virus-associated cirrhosis].
Kim
Hyung Joon
HJ
Department of Internal Medicine, Chungang University College of Medicine, Seoul, Korea.
D004359:Drug Therapy, Combination; D016174:Hepacivirus; D019698:Hepatitis C, Chronic / Q000150:complications / Q000175:diagnosis* / Q000628:therapy; D006801:Humans; D000077190:Interferon alpha-2; D016898:Interferon-alpha / Q000627:therapeutic use; D008103:Liver Cirrhosis / Q000175:diagnosis* / Q000401:mortality / Q000821:virology; D016031:Liver Transplantation; D019520:Living Donors; D011092:Polyethylene Glycols / Q000627:therapeutic use; D011994:Recombinant Proteins; D012254:Ribavirin / Q000627:therapeutic use; D012720:Severity of Illness Index; D016896:Treatment Outcome
D000077190:Interferon alpha-2; D016898:Interferon-alpha; D011994:Recombinant Proteins; D011092:Polyethylene Glycols; D012254:Ribavirin; C100416:peginterferon alfa-2a